当前位置: 首页 > 期刊 > 《中国实用医药》 > 2011年第32期 > 正文
编号:12149661
重组人干扰素治疗疱疹性咽炎123例疗效分析(1)
http://www.100md.com 2011年11月15日 房满 赵丽华 裘秀月
第1页

    参见附件(2367KB,2页)。

     【摘要】 目的 观察重组人干扰素治疗小儿疱疹性咽炎的临床疗效。方法 将临床确诊疱疹性咽炎的230例患儿随机分为治疗组和对照组。两组常规预防感染及对症治疗,治疗组123例患儿给予重组人干扰素1 μg/(kg•次),1次/d,肌内注射,连续3 d;对照组107例患儿给予病毒唑10 mg/(kg•d)静脉滴注,1次/d,连续3 d。观察治疗前后患儿的临床症状及体征。结果 治疗组总有效率(98.38%)、热程(3.74±2.3)d,咽部充血及疱疹平均消退时间(4.64±2.3)d,住院期(6.44±2.1)d;对照组总有效率(80.37%)、热程(4.32±2.6)d,咽部充血及疱疹平均消退时间(6.84±2.3)d,住院期(9.3±1.1)d。治疗组在退热时间、疱疹消退时间及住院期方面明显优于对照组(P<0.05)。结论 重组人干扰素治疗小儿疱疹性咽炎可较快改善病情、缩短病程、提高疗效。

    【关键词】 疱疹性咽炎;重组人干扰素;疗效

    The clinical efficacy of recombinant human interferon in the treatment of herpes pharyngitis for 123 cases FANG Man, ZHAO Li,hua, QIU Xiu,yue.Department of Pediatric,Shenyang Red Cross Hospital,Shenyang 110013,China

    【Abstract】 Objective To explore the clinical efficacy of recombinant human interferon in treatment of pediatric herpes pharyngitis. Methods 230 patients diagnosed with herpes pharyngitis were randomly divided into treatment and control groups. Patients of two groups were treated with conventional prevention of infection and symptomatic treatment. The 123 patients of treatment group were also given recombinant human interferon (1 μg/kg, im. 1 times /d, for 3 days). 107 patiets of control group were treated with ribavirin [10 mg/(kg•d), iv.1 times/d, for 3 days].The clinical symptoms and signs, radiological and laboratory data of these patients were retrospectively evaluated. Results In the treatment group, the overall response rate was 98.38%, the median time of thermal process was (3.74± 2.3)d, the median period of throat congestion and herpes was (4.64± 2.3)d, and length of stay (6.44± 2.1)d. In the control group, the total efficiency was 80.37%, the median time of thermal process was (4.32± 2.6)d, throat congestion and the median time of herpes was (6.84± 2.3)d, and length of stay (9.3± 1.1)d. Cooling time, the period of herpes and length of stay of patients in the treatment group was significantly better than that of patients in the control group (P<0.05). Conclusion Recombinant human interferon in the treatment of pediatic herpes pharyngitis can rapidly improve the condition of patients and efficacy, induce the length of stay ......

您现在查看是摘要介绍页,详见PDF附件(2367KB,2页)